ArticleJournal of clinical pathology2007
Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL.
Article in Journal of clinical pathology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Article
- Acute lymphoblastic leukemia in children and SALL4 and BMI-1 gene expression.Pediatric research · 2023Article
- Lymphocyte to monocyte ratio predicts survival and is epigenetically linked to miR-222-3p and miR-26b-5p in diffuse large B cell lymphoma.Scientific reports · 2023Article
- Internal Ribosome Entry Sites Mediate Cap-Independent Translation of Bmi1 in Nasopharyngeal Carcinoma.Frontiers in oncology · 2020Article
- Polycomb complexes in normal and malignant hematopoiesis.The Journal of cell biology · 2019Review
- BMI1 reduces ATR activation and signalling caused by hydroxyurea.Oncotarget · 2017Article
- Upregulation of the proto-oncogene Bmi-1 predicts a poor prognosis in pediatric acute lymphoblastic leukemia.BMC cancer · 2017Article
- The roles of Polycomb group proteins in hematopoietic stem cells and hematological malignancies.International journal of hematology · 2016Review
- Context-dependent actions of Polycomb repressors in cancer.Oncogene · 2016Review
- The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- EZH2 in normal hematopoiesis and hematological malignancies.Oncotarget · 2016Review
- BMI1: A Biomarker of Hematologic Malignancies.Biomarkers in cancer · 2016Review
- Targeting EZH2 and PRC2 dependence as novel anticancer therapy.Experimental hematology · 2015Review
- Article
- Review
- In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2.Virchows Archiv : an international journal of pathology · 2013Article
- Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins.Nature reviews. Cancer · 2010Review
- PTEN inhibits BMI1 function independently of its phosphatase activity.Molecular cancer · 2009Article
- Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical outcome in patients with diffuse large B cell lymphomas (DLBCL) is highly variable and poorly predictable. Microarray studies showed that patients with DLBCL with a germinal centre B cell-like (GCB) phenotype have a better prognosis than those with an activated B cell-like (ABC) phenotype. The BMI1 proto-oncogene was identified as one of the genes present in the signature of the ABC type of DLBCL, associated with a poor prognosis.
objectives(1) To investigate, in primary nodal DLBCL, the expression of BMI1 and its association with clinical outcome and DLBCL signature; (2) to look for an association between BMI1 expression and the expression of its putative downstream targets p14ARF and p16INK4a.
resultsBMI1 expression was found to be associated with poor clinical outcome, but not clearly with an ABC-like phenotype of DLBCL. Expression of BMI1 was frequently, but not always, related to low levels of expression of p14ARF and p16INK4a.
conclusionExpression of BMI1 is associated with an unfavourable clinical outcome of primary nodal DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.